Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

What Happened: Skovronsky demonstrated confidence in Eli Lilly by purchasing 1,000 shares, as reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an ...

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...